APA (7th ed.) Citation

C, W., Z, W., J, Z., B, C., & Y, H. (2025). Semaglutide, a glucagon-like peptide-1 receptor agonist, inhibits oral squamous cell carcinoma growth through P38 MAPK signaling pathway. Journal of cancer research and clinical oncology, 151(3), 103. https://doi.org/10.1007/s00432-025-06154-5

Chicago Style (17th ed.) Citation

C, Wang, Wu Z, Zhou J, Cheng B, and Huang Y. "Semaglutide, a Glucagon-like Peptide-1 Receptor Agonist, Inhibits Oral Squamous Cell Carcinoma Growth Through P38 MAPK Signaling Pathway." Journal of Cancer Research and Clinical Oncology 151, no. 3 (2025): 103. https://doi.org/10.1007/s00432-025-06154-5.

MLA (9th ed.) Citation

C, Wang, et al. "Semaglutide, a Glucagon-like Peptide-1 Receptor Agonist, Inhibits Oral Squamous Cell Carcinoma Growth Through P38 MAPK Signaling Pathway." Journal of Cancer Research and Clinical Oncology, vol. 151, no. 3, 2025, p. 103, https://doi.org/10.1007/s00432-025-06154-5.